These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36460182)

  • 21. Management of tenosynovial giant cell tumour of the foot and ankle.
    Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH
    Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis).
    Gouin F; Noailles T
    Orthop Traumatol Surg Res; 2017 Feb; 103(1S):S91-S97. PubMed ID: 28057477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function.
    Verspoor FGM; Mastboom MJL; Hannink G; van der Graaf WTA; van de Sande MAJ; Schreuder HWB
    Bone Joint J; 2019 Mar; 101-B(3):272-280. PubMed ID: 30813787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spinal pigmented villonodular synovitis and tenosynovial giant cell tumor: A report of two cases and a comprehensive systematic review.
    Zeoli T; Mathkour M; Scullen T; Carr C; Abou-Al-Shaar H; Wang L; Divagaran A; Dindial R; Tubbs RS; Bui CJ; Maulucci CM
    Clin Neurol Neurosurg; 2021 Mar; 202():106489. PubMed ID: 33596487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distraction arthroplasty combined with autologous bone grafting for diffuse-type tenosynovial giant cell tumour with articular cartilage defect and subchondral bone cysts: A case report.
    Ikuta Y; Nakasa T; Sumii J; Nekomoto A; Kawabata S; Adachi N
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):483-487. PubMed ID: 36484489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: A case report.
    Geiger EJ; Jensen AR; Singh AS; Nelson SD; Bernthal NM
    J Orthop Sci; 2024 Jan; 29(1):458-462. PubMed ID: 36402606
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
    Spierenburg G; Grimison P; Chevreau C; Stacchiotti S; Piperno-Neumann S; Le Cesne A; Ferraresi V; Italiano A; Duffaud F; Penel N; Metzger S; Chabaud S; van der Heijden L; Pérol D; van de Sande MAJ; Blay JY; Gelderblom H
    Eur J Cancer; 2022 Sep; 173():219-228. PubMed ID: 35932628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee.
    Dürr HR; Capellen CF; Klein A; Baur-Melnyk A; Birkenmaier C; Jansson V; Tiling R
    Arch Orthop Trauma Surg; 2019 May; 139(5):623-627. PubMed ID: 30539286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lowering the recurrence rate in pigmented villonodular synovitis: A series of 120 resections.
    Capellen CF; Tiling R; Klein A; Baur-Melnyk A; Knösel T; Birkenmaier C; Roeder F; Jansson V; Dürr HR
    Rheumatology (Oxford); 2018 Aug; 57(8):1448-1452. PubMed ID: 29788491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints: A Study Based on a Multicenter-Pooled Database of 31 International Sarcoma Centers.
    Mastboom MJL; Staals EL; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Palmerini E; Schaap GR; Jutte PC; Aston W; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; van de Sande MAJ;
    J Bone Joint Surg Am; 2019 Jul; 101(14):1309-1318. PubMed ID: 31318811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Burden of Illness Associated with Tenosynovial Giant Cell Tumors.
    Burton TM; Ye X; Parker ED; Bancroft T; Healey J
    Clin Ther; 2018 Apr; 40(4):593-602.e1. PubMed ID: 29580718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined arthroscopic and open synovectomy for diffuse pigmented villonodular synovitis of the knee.
    Mollon B; Griffin AM; Ferguson PC; Wunder JS; Theodoropoulos J
    Knee Surg Sports Traumatol Arthrosc; 2016 Jan; 24(1):260-6. PubMed ID: 25308157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse and localized tenosynovial giant cell tumor and pigmented villonodular synovitis: a clinicopathologic and flow cytometric DNA analysis.
    Abdul-Karim FW; el-Naggar AK; Joyce MJ; Makley JT; Carter JR
    Hum Pathol; 1992 Jul; 23(7):729-35. PubMed ID: 1319390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon's Perspective.
    Bernthal NM; Ishmael CR; Burke ZDC
    Curr Oncol Rep; 2020 Jun; 22(6):63. PubMed ID: 32494892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A New Simple and Practical Clinical Classification for Tenosynovial Giant Cell Tumors of the Knee.
    Zheng K; Yu XC; Hu YC; Xu M; Zhang JY
    Orthop Surg; 2022 Feb; 14(2):290-297. PubMed ID: 34914180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.
    Bernthal NM; Healey JH; Palmerini E; Bauer S; Schreuder H; Leithner A; Martin-Broto J; Gouin F; Lopez-Bastida J; Gelderblom H; Staals EL; Burke ZD; Geiger EJ; Spierenburg G; Laeis P; Beyerlein E; Ye X; van de Sande M
    J Surg Oncol; 2022 Dec; 126(8):1520-1532. PubMed ID: 36006054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse-Type Tenosynovial Giant Cell Tumor An Update of Current Management Strategies.
    Naja A; Abboud A; Masrouha K; Ghert M; Saghieh S
    Bull Hosp Jt Dis (2013); 2024 Sep; 82(3):178-185. PubMed ID: 39150871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study.
    Spierenburg G; Staals EL; Palmerini E; Randall RL; Thorpe SW; Wunder JS; Ferguson PC; Verspoor FGM; Houdek MT; Bernthal NM; Schreuder BHWB; Gelderblom H; van de Sande MAJ; van der Heijden L
    Eur J Surg Oncol; 2024 Feb; 50(2):107953. PubMed ID: 38215550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.